Mario Maldonado

2.8k total citations · 1 hit paper
25 papers, 1.4k citations indexed

About

Mario Maldonado is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Genetics. According to data from OpenAlex, Mario Maldonado has authored 25 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Surgery and 7 papers in Genetics. Recurrent topics in Mario Maldonado's work include Pituitary Gland Disorders and Treatments (11 papers), Diabetes and associated disorders (7 papers) and Pancreatic function and diabetes (7 papers). Mario Maldonado is often cited by papers focused on Pituitary Gland Disorders and Treatments (11 papers), Diabetes and associated disorders (7 papers) and Pancreatic function and diabetes (7 papers). Mario Maldonado collaborates with scholars based in United States, Switzerland and United Kingdom. Mario Maldonado's co-authors include Ashok Balasubramanyam, Stephan Petersenn, James W. Findling, John Newell‐Price, Christiane S. Hampe, Annamaria Colao, Feng Gu, U Schoenherr, David Mills and Luiz Roberto Salgado and has published in prestigious journals such as New England Journal of Medicine, American Journal of Clinical Nutrition and Endocrine Reviews.

In The Last Decade

Mario Maldonado

25 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

2012 442 citations Annamaria Colao, Stephan Petersenn et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Mario Maldonado

Since Specialization

Citations

This map shows the geographic impact of Mario Maldonado's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Maldonado with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Maldonado more than expected).

Fields of papers citing papers by Mario Maldonado

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mario Maldonado. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Maldonado. The network helps show where Mario Maldonado may publish in the future.

Co-authorship network of co-authors of Mario Maldonado

This figure shows the co-authorship network connecting the top 25 collaborators of Mario Maldonado. A scholar is included among the top collaborators of Mario Maldonado based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Maldonado. Mario Maldonado is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome 2025 ·The Journal of Clinical Endocrinology & Metabolism ·Antoine Tabarin, Jérôme Bertherat, Bénédicte Decoudier, Hélène Lasolle, Hervé Lefèbvre, D. Drui, (unknown), J. Morera, Frédéric Castinetti, Justine Cristante, Nicolas Chevalier, (unknown), (unknown), (unknown), (unknown), Mario Maldonado, (unknown), (unknown)	2
2	Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study 2014 ·Clinical Endocrinology ·Rosario Pivonello, Stephan Petersenn, John Newell‐Price, James W. Findling, Feng Gu, Mario Maldonado, A Trovato, Gareth Hughes, L R Salgado, André Lacroix, Jochen Schopohl, (unknown), (unknown)	84
3	Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease 2014 ·European Journal of Endocrinology ·Susan M. Webb, John E. Ware, Anna Forsythe, Min Yang, Xavier Badı́a, Lauren Nelson, James Signorovitch, Lori McLeod, Mario Maldonado, Wojciech Zgliczyński, Christophe De Block, Lesly Portocarrero-Ortíz, Mônica R. Gadelha	23
4	Psychometric Evaluation of the Cushing’s Quality-of-Life Questionnaire 2013 ·Patient ·Lauren Nelson, Anna Forsythe, Lori McLeod, Sonia Pulgar, Mario Maldonado, Theresa Coles, Yanqiong Zhang, Susan M. Webb, Xavier Badı́a	33
5	High variability in baseline urinary free cortisol values in patients with Cushing's disease 2013 ·Clinical Endocrinology ·Stephan Petersenn, John Newell‐Price, James W. Findling, Feng Gu, Mario Maldonado, (unknown), L R Salgado, Annamaria Colao, Beverly M. K. Biller, (unknown)	95
6	LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study 2013 ·The Journal of Clinical Endocrinology & Metabolism ·Xavier Bertagna, Rosario Pivonello, Maria Fleseriu, Yiming Zhang, (unknown), Ann E. Taylor, Catherine E. Watson, Mario Maldonado, Amir H. Hamrahian, Marco Boscaro, Beverly M. K. Biller	144
7	Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study 2013 ·Pituitary ·Marco Boscaro, Jérôme Bertherat, James W. Findling, Maria Fleseriu, A. B. Atkinson, Stephan Petersenn, Jochen Schopohl, Peter J. Snyder, Gareth Hughes, A Trovato, Ke Hu, Mario Maldonado, Beverly M. K. Biller	42
8	A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease breakdown → 2012 ·New England Journal of Medicine ·Annamaria Colao, Stephan Petersenn, John Newell‐Price, James W. Findling, Feng Gu, Mario Maldonado, U Schoenherr, (unknown), David Mills, Luiz Roberto Salgado, (unknown)	442
9	Tolerability and Dose Proportional Pharmacokinetics of Pasireotide Administered as a Single Dose or Two Divided Doses in Healthy Male Volunteers: A Single-Center, Open-Label, Ascending-Dose Study 2012 ·Clinical Therapeutics ·Stephan Petersenn, Ke Hu, Mario Maldonado, Yilong Zhang, Janet Lasher, (unknown), Yanfeng Wang, Klaus Mann, Nicole Unger	14
10	An Open-Label Dose-Escalation Study of Once-Daily and Twice-Daily Pasireotide in Healthy Volunteers 2012 ·American Journal of Therapeutics ·Magdy Shenouda, Mario Maldonado, Yanfeng Wang, (unknown), Michelle Hudson, (unknown), Ke Hu	23
11	Presence or absence of a known diabetic ketoacidosis precipitant defines distinct syndromes of “A-β+” ketosis-prone diabetes based on long-term β-cell function, human leukocyte antigen class II alleles, and sex predilection 2010 ·Metabolism ·Ramaswami Nalini, (unknown), Mario Maldonado, Sanjeet Patel, Christiane S. Hampe, (unknown), Jesus A. Villanueva, E. O’Brian Smith, Lakshmi K. Gaur, Ashok Balasubramanyam	40
12	Syndromes of Ketosis-Prone Diabetes Mellitus 2008 ·Endocrine Reviews ·Ashok Balasubramanyam, Ramaswami Nalini, Christiane S. Hampe, Mario Maldonado	124
13	Regression of acanthosis nigricans correlates with disappearance of anti–insulin receptor autoantibodies and achievement of euglycemia in type B insulin resistance syndrome 2007 ·Metabolism ·(unknown), Mario Maldonado, Elif A Oral, Ashok Balasubramanyam	25
14	Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome 2006 ·American Journal of Clinical Nutrition ·(unknown), Jianjian Shi, Rajagopal V. Sekhar, Farook Jahoor, Kenneth J. Ellis, (unknown), James Willis, Mario Maldonado, Ashok Balasubramanyam	15
15	Predictors of glycaemic control in indigent patients presenting with diabetic ketoacidosis 2005 ·Diabetes Obesity and Metabolism ·Mario Maldonado, (unknown), Max E. Otiniano, Ashok Balasubramanyam, Luisa M. Rodríguez, (unknown)	9
16	Presence of the metabolic syndrome distinguishes patients with ketosis-prone diabetes who have a Type 2 diabetic phenotype 2005 ·Journal of Diabetes and its Complications ·Max E. Otiniano, Ashok Balasubramanyam, Mario Maldonado	16
17	Fenofibrate Is Effective in Treating Hypertriglyceridemia Associated with HIV Lipodystrophy 2004 ·The American Journal of the Medical Sciences ·(unknown), (unknown), Ashok Balasubramanyam, Mario Maldonado	31
18	Diabetic ketoacidosis associated with Metabolife: a report of two cases 2002 ·Diabetes Obesity and Metabolism ·Christopher Case, Mario Maldonado	5
19	Sarcoidosis After Surgically Induced Remission of Cushing’s Disease 1999 ·Endocrine Practice ·Mario Maldonado, (unknown), (unknown), Ian E. McCutcheon, Karen R. Cleary, Keith Friend	3
20	Sadness, depression and social reciprocity in highland Ecuador 1989 ·Social Science & Medicine ·Michel Tousignant, Mario Maldonado	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact